Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.
Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.